Evinature

Company Overview

Snapshot

Founded in April 2021 by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., and Nir Salomon ChB, Evinature operates with 11–50 employees. The company has raised $6.5M across three funding rounds, focusing on developing evidence-based nutraceuticals. In July 2024, Evinature was recognized as a top Health Tech company in Startup Nation's H1 2024 Israeli Tech Report, highlighting its growing prominence in the sector.

Business overview

Evinature develops and offers clinically proven, evidence-based nutraceuticals for gut health, blending modern science with traditional botanical knowledge. The company provides natural, well-researched solutions, including personalized guidance and ongoing digital check-ins, with optional clinic-based support. Evinature serves health-minded communities worldwide, operating within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting patients with conditions like Inflammatory Bowel Disease (IBD).

Strategic signal

Evinature is demonstrating significant progress in clinical validation and market penetration for its CurQD® protocol. In September 2024, a multicenter retrospective cohort study on the efficacy of CurQD in children with active ulcerative colitis was published in Frontiers in Pediatrics, providing robust scientific backing for its product. This publication, alongside the company's integration across 35 US medical centers by April 2024, signals strong momentum in both clinical acceptance and accessibility for its IBD treatments, positioning Evinature for continued growth and broader adoption.

Company Intelligence Q&A

What is Evinature's core focus?

Evinature focuses on developing clinically proven, evidence-based nutraceuticals for gut health, combining modern science with traditional botanical knowledge to offer natural and well-researched solutions.

What was a key finding regarding Evinature's CurQD® protocol in November 2024?

In November 2024, Evinature's CurQD® was found to be successful in a pediatric trial for reducing symptoms of IBD, as reported on the company's blog.

What significant distribution deal did Evinature sign in August 2023?

In August 2023, Evinature signed an exclusive distribution deal with multinational company Adacyte Therapeutics to expand IBD treatment accessibility.

How has Evinature expanded its reach within the US medical system?

By April 2024, healthcare startup Evinature became integrated across 35 US medical centers to further streamline IBD treatment accessibility.

What recognition did Evinature receive in July 2024?

In July 2024, Evinature was listed among the top Health Tech companies in Startup Nation's H1 2024 Israeli Tech Report, highlighting its prominence in the sector.